DK2723323T3 - Frysetørring af syntetisk liposomal pulmonært overfladeaktivt stof - Google Patents
Frysetørring af syntetisk liposomal pulmonært overfladeaktivt stof Download PDFInfo
- Publication number
- DK2723323T3 DK2723323T3 DK13716655.9T DK13716655T DK2723323T3 DK 2723323 T3 DK2723323 T3 DK 2723323T3 DK 13716655 T DK13716655 T DK 13716655T DK 2723323 T3 DK2723323 T3 DK 2723323T3
- Authority
- DK
- Denmark
- Prior art keywords
- freeze
- temperature
- mixture
- drying
- pulmonary surfactant
- Prior art date
Links
- 239000003580 lung surfactant Substances 0.000 title claims description 86
- 238000004108 freeze drying Methods 0.000 title claims description 71
- 239000000203 mixture Substances 0.000 claims description 155
- 238000000034 method Methods 0.000 claims description 65
- 239000003960 organic solvent Substances 0.000 claims description 55
- 238000001035 drying Methods 0.000 claims description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 44
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 42
- 230000008569 process Effects 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 238000005339 levitation Methods 0.000 claims description 29
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 25
- 238000000137 annealing Methods 0.000 claims description 25
- 230000008014 freezing Effects 0.000 claims description 24
- 238000007710 freezing Methods 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 22
- 235000021314 Palmitic acid Nutrition 0.000 claims description 21
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 238000001816 cooling Methods 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 10
- PAZGBAOHGQRCBP-ZCXUNETKSA-N 1-Palmitoyl-2-oleoylglycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-ZCXUNETKSA-N 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000013557 residual solvent Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000013508 migration Methods 0.000 claims description 3
- 230000005012 migration Effects 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 57
- 239000000463 material Substances 0.000 description 49
- 239000012071 phase Substances 0.000 description 36
- 239000000047 product Substances 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 239000007788 liquid Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 20
- 229940066294 lung surfactant Drugs 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 239000008186 active pharmaceutical agent Substances 0.000 description 15
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 15
- 238000012792 lyophilization process Methods 0.000 description 15
- 150000003904 phospholipids Chemical class 0.000 description 15
- 238000000859 sublimation Methods 0.000 description 14
- 230000008022 sublimation Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 238000007711 solidification Methods 0.000 description 10
- 230000008023 solidification Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- -1 for example Substances 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 239000011148 porous material Substances 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 239000012931 lyophilized formulation Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000002076 thermal analysis method Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000009477 glass transition Effects 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000007669 thermal treatment Methods 0.000 description 3
- 230000008016 vaporization Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- QSIRXSYRKZHJHX-TWXHAJHVSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-4-methylpen Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O QSIRXSYRKZHJHX-TWXHAJHVSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 101001067830 Mus musculus Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000005388 borosilicate glass Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000008364 bulk solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 229910052743 krypton Inorganic materials 0.000 description 2
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108010015964 lucinactant Proteins 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 108010081062 sinapultide Proteins 0.000 description 2
- 229960000802 sinapultide Drugs 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229920001664 tyloxapol Polymers 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- 229960004224 tyloxapol Drugs 0.000 description 2
- 238000010977 unit operation Methods 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000010964 304L stainless steel Substances 0.000 description 1
- PTOVOAJZRWYLQM-GOSISDBHSA-N 6-[2-[3-fluoro-5-[2-[(2S)-pyrrolidin-2-yl]ethyl]phenyl]ethyl]-4-methylpyridin-2-amine Chemical compound Cc1cc(N)nc(CCc2cc(F)cc(CC[C@H]3CCCN3)c2)c1 PTOVOAJZRWYLQM-GOSISDBHSA-N 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010073688 KL4 surfactant Proteins 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 1
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 1
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 1
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 1
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 1
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- QEGNUYASOUJEHD-UHFFFAOYSA-N gem-dimethylcyclohexane Natural products CC1(C)CCCCC1 QEGNUYASOUJEHD-UHFFFAOYSA-N 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 239000013529 heat transfer fluid Substances 0.000 description 1
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- KVYJZMJPHSXEDZ-UHFFFAOYSA-N pentan-1-ol Chemical compound CCCCCO.CCCCCO KVYJZMJPHSXEDZ-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940080796 surfaxin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0082—Lung surfactant, artificial mucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Claims (13)
1. Fremgangsmåde til fremstilling af et frysetørret syntetisk pulmonært overfladeaktivt stof med en mindsket eller elimineret kagelevitation under fremgangsmåden, fremgangsmåden omfattende: at tilvejebringe til et frysetørringskammer en præfrysetørringsblanding omfattende dipalmitoylphosphatidylcholin (DPPC), palmitoyloleoylphosphatidylglycerol (POPG), palmitinsyre og et syntetisk peptid med SEQ ID NO: 1 (KL4 polypeptid) dispergeret i et solvent med en organisk solvent i et område på mellem 3% (vol./vol.) og under 20% (vol./vol.) af den samlede volumen af præfrysetørringsblandingen hvor en resterende del er vand og/eller buffer, hvor præfrysetørringsblandingen fyldes i en beholder; at sænke en temperatur inden i frysetørringskammeret til at begynde at nedkøle og størkne præfrysetørringsblandingen i en frysefase hvor frysefasen omfatter at nedkøle præfrysetørringsblandingen til en første temperatur på -45°C eller under -45°C med en hastighed mellem 0,1 og 1,0°C pr. minut og at holde præfrysetørringsblandingen ved den første temperatur i en første tidsperiode tilstrækkelig til at størkne mindst 76% af solventen for at danne en første størknet blanding; at udføre en annealingfase forud for en primær tørringsfase og derved mindske eller eliminere kagelevitation af den første størknede blanding og i det frysetørrede syntetiske pulmonære overfladeaktive stof, hvor annealingfasen omfatter (i) at varme den første størknede blanding til en anden temperatur valgt til at mindske eller eliminere levitation af den første størknede blanding, (ii) at holde den første størknede blanding ved den anden temperatur i en anden tidsperiode tilstrækkelig til at mindske eller eliminere levitation af den første størknede blanding, og (iii) at nedkøle den første størknede blanding til en tredje temperatur på -45°C eller under -45°C med en hastighed mellem 0,1 til 1,0°C pr. minut for at danne en anden størknet blanding, hvor den anden størknede blanding holdes ved den tredje temperatur i en tredje tidsperiode tilstrækkelig til at fremme separation af optøet organisk solvent fra den anden størknede blanding og derved opnå en migration af den optøede organiske solvent til en grænseflade mellem beholderen og den anden størknede blanding; at udføre en primær tørringsfase ved et mindsket tryk på 30 mT eller højere, hvor den anden størknede blanding holdes ved den tredje temperatur i en fjerde tidsperiode tilstrækkelig til at fjerne mindst 5% af den organiske solvent, efterfulgt af at opvarme til en fjerde temperatur tilstrækkelig til at afholde den anden størknede blanding fra at levitere i beholderen og fastholde en struktur etableret under annealingfasen, og yderligere holdt ved den fjerde temperatur i en femte tidsperiode tilstrækkelig til at fjerne mindst 70% af solventen og derved danne en tredje størknet blanding; og at udføre en sekundær tørringsfase ved det mindskede tryk i en sjette tidsperiode tilstrækkelig til at fremstille det frysetørrede syntetiske pulmonære overfladeaktive stof med et residualsolventindhold på højst 2%; hvor det frysetørrede syntetiske pulmonære overfladeaktive stof har et specifikt overfladeareal på mindst 2,2 m2/g.
2. Fremgangsmåden ifølge krav 1, hvor et forhold mellem præfrysetørringsblandingens volumen i beholderen og beholderens volumen er fra 28% til 68%.
3. Fremgangsmåden ifølge krav 1, hvor et forhold mellem en højde af præfrysetørringsblandingen i beholderen og beholderens diameter er i området fra 0,3 til 0,8.
4. Fremgangsmåden ifølge krav 1, fremgangsmåden omfattende at tilvejebringe præfrysetørringsblandingen hvor den organiske solvent er i området fra 3% til 15%.
5. Fremgangsmåden ifølge krav 1, fremgangsmåden omfattende at tilvejebringe præfrysetørringsblandingen hvor den organiske solvent er i området fra 5% til 10%.
6. Fremgangsmåden ifølge krav 1, fremgangsmåden omfattende at tilvejebringe præfrysetørringsblandingen hvor den organiske solvent er i området fra 7% til 10%.
7. Fremgangsmåden ifølge et hvilket som helst af kravene 1-6, fremgangsmåden omfattende: at udføre frysefasen, hvor præfrysetørringsblandingen nedkøles til den første temperatur på - 50°C± 5°C med en hastighed mellem 0,1 og l,0°C/min; at udføre annealingfasen, hvor den første størknede blanding (i) opvarmes til den anden temperatur på - 22°C ± 5°C med en hastighed på 0,1 til l,0°C/min, (ii) holdes ved den anden temperatur i den anden tidsperiode mellem 3 og 8 timer, (iii) nedkøles til den tredje temperatur på - 50°C ± 5°C med en hastighed mellem 0,1 til l,0°C/min; og (iv) holdes ved den tredje temperatur i den tredje tidsperiode i 3 til 8 timer; at udføre den primære tørringsfase ved et tryk valgt fra området af 30mT til 200mT og en primær tørringstemperatur valgt fra området fra -25°C til 0°C øget fra - 50°C ± 5°C, og yderligere holdes ved den primære tørring i mindst 10 timer.
8. Fremgangsmåden ifølge et hvilket som helst af kravene 1-7, fremgangsmåden omfattende at udføre den sekundære tørringsfase ved et tryk valgt fra området fra 30mT til 200mT og temperatur på højst 46°C± 5°C.
9. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 8, hvor det specifikke overfladeareal er i området fra 3,7 m2/g til 2,2 m2/g.
10. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 8, hvor det frysetørrede syntetiske pulmonære overfladeaktive stof har porøsitet over 40 volumenprocent af et samlet areal af det frysetørrede syntetiske pulmonære overfladeaktive stof.
11. Frysetørret syntetisk pulmonært overfladeaktivt stof-sammensætning omfattende: et syntetisk polypeptid med SEQ ID NO: 1 (KL4 polypeptid), dipalmitoylphosphatidylcholin (DPPC), palmitoyloleoylphosphatidylglycerol (POPG) og palmitinsyre, hvor den frysetørrede syntetiske pulmonære overfladeaktive stof-sammensætning har et specifikt overfladeareal på mindst 2,2 m2/g.
12. Det frysetørrede syntetiske pulmonære overfladeaktive stof ifølge krav 11, hvor det specifikke overfladeareal er i området fra 3,7 m2/g til 2,2 m2/g.
13. Det frysetørrede syntetiske pulmonære overfladeaktive stof ifølge krav 11, hvor det frysetørrede syntetiske pulmonære overfladeaktive stof har porøsitet over 40 volumenprocent af et samlet areal af det frysetørrede syntetiske pulmonære overfladeaktive stof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261616827P | 2012-03-28 | 2012-03-28 | |
PCT/US2013/034464 WO2013149074A1 (en) | 2012-03-28 | 2013-03-28 | Lyophilization of synthetic liposomal pulmonary surfactant |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2723323T3 true DK2723323T3 (da) | 2016-01-11 |
Family
ID=48096305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13716655.9T DK2723323T3 (da) | 2012-03-28 | 2013-03-28 | Frysetørring af syntetisk liposomal pulmonært overfladeaktivt stof |
Country Status (35)
Country | Link |
---|---|
US (3) | US9554999B2 (da) |
EP (2) | EP2837377A1 (da) |
JP (1) | JP6178402B2 (da) |
KR (1) | KR102123129B1 (da) |
CN (1) | CN104271118B (da) |
AU (2) | AU2013237985B2 (da) |
BR (1) | BR112014024057A8 (da) |
CA (1) | CA2867649C (da) |
CL (1) | CL2014002553A1 (da) |
CO (1) | CO7081146A2 (da) |
CR (1) | CR20140449A (da) |
CU (1) | CU20140116A7 (da) |
CY (1) | CY1117380T1 (da) |
DK (1) | DK2723323T3 (da) |
EC (1) | ECSP14024363A (da) |
ES (1) | ES2557805T3 (da) |
HK (3) | HK1197174A1 (da) |
HR (1) | HRP20151392T1 (da) |
HU (1) | HUE026363T2 (da) |
IL (1) | IL234688B (da) |
IN (1) | IN2014DN08538A (da) |
MA (1) | MA37445B1 (da) |
MX (1) | MX359654B (da) |
MY (1) | MY164868A (da) |
NZ (1) | NZ630219A (da) |
PE (1) | PE20142302A1 (da) |
PL (1) | PL2723323T3 (da) |
PT (1) | PT2723323E (da) |
RS (1) | RS54513B1 (da) |
RU (1) | RU2671500C2 (da) |
SG (1) | SG11201405944PA (da) |
SI (1) | SI2723323T1 (da) |
SM (1) | SMT201500320B (da) |
WO (2) | WO2013149013A1 (da) |
ZA (1) | ZA201406982B (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE026363T2 (en) * | 2012-03-28 | 2016-06-28 | Discovery Lab Inc | Lyophilization of pulmonary synthetic liposomal surfactant |
WO2016080336A1 (ja) * | 2014-11-18 | 2016-05-26 | 国立研究開発法人物質・材料研究機構 | 多孔性粒子の製造方法 |
KR101801566B1 (ko) * | 2014-12-30 | 2017-11-28 | 주식회사 삼양바이오팜 | 고분자 나노입자 동결건조물 및 그 제조방법 |
EP3319597B1 (en) * | 2015-07-10 | 2021-02-17 | Byondis B.V. | Compositions comprising antibody-duocarmycin drug conjugates |
IL288342B2 (en) | 2015-07-22 | 2024-02-01 | Nitto Denko Corp | Formulations and methods for lyophilic nanoparticulate forms |
JP7012512B2 (ja) * | 2017-11-13 | 2022-01-28 | 清水建設株式会社 | 管理装置、製造システムおよび管理方法 |
EP3727353A4 (en) * | 2017-12-21 | 2021-10-13 | Civitas Therapeutics, Inc. | SURFACTANT FORMULATIONS FOR INHALATION |
CN108853061A (zh) * | 2018-10-09 | 2018-11-23 | 兆科药业(合肥)有限公司 | 一种人工合成肺表面活性剂药物组合物及与之的肠溶胶囊和其制备方法及用途 |
WO2020142420A1 (en) * | 2018-12-31 | 2020-07-09 | Novus Therapeutics, Inc. | Novel surfactant-lipid alloy drug substance, methods of making the same, and pharmaceutical compositions comprising the same |
US11287185B1 (en) | 2020-09-09 | 2022-03-29 | Stay Fresh Technology, LLC | Freeze drying with constant-pressure and constant-temperature phases |
KR102545292B1 (ko) * | 2021-01-28 | 2023-06-16 | 인천대학교 산학협력단 | 마이크로캡슐 형성용 생체 적합 계면활성제 합성방법 |
AR126368A1 (es) * | 2021-07-05 | 2023-10-11 | Chiesi Farm Spa | Proceso para la preparación de un tensioactivo pulmonar |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE751108R (fr) | 1969-06-06 | 1970-11-03 | Berliet Automobiles | Dispositif pour la mesure precise de la consommation specifiquedes moteurs a combustion |
JPS59164724A (ja) * | 1983-03-10 | 1984-09-17 | Tokyo Tanabe Co Ltd | サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤 |
US5260273A (en) | 1988-01-06 | 1993-11-09 | The Scripps Research Institute | Pulmonary surfactant protein and related polypeptide |
KR100449789B1 (ko) | 1996-01-24 | 2005-02-03 | 알타나 파마 아게 | 분말형폐계면활성제제의제조방법 |
WO1997035882A1 (en) * | 1996-03-27 | 1997-10-02 | Ortho Pharmaceutical Corporation | Lyophilized pulmonary surfactant peptide compositions |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US7638493B2 (en) | 2004-04-29 | 2009-12-29 | Sannamu Lee | Artificial pulmonary surfactant compositions and use of the same |
US7582312B2 (en) * | 2004-11-15 | 2009-09-01 | Discovery Laboratories, Inc. | Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof |
EP2377554A1 (en) | 2005-07-22 | 2011-10-19 | Amgen, Inc | Concentrated protein lyophilates, methods and uses |
EP1997502A1 (en) | 2007-06-01 | 2008-12-03 | CHIESI FARMACEUTICI S.p.A. | Reconstituted surfactants having improved properties |
HUE026363T2 (en) * | 2012-03-28 | 2016-06-28 | Discovery Lab Inc | Lyophilization of pulmonary synthetic liposomal surfactant |
-
2013
- 2013-03-28 HU HUE13716655A patent/HUE026363T2/en unknown
- 2013-03-28 RU RU2014143247A patent/RU2671500C2/ru active
- 2013-03-28 EP EP14188473.4A patent/EP2837377A1/en not_active Withdrawn
- 2013-03-28 MY MYPI2014002699A patent/MY164868A/en unknown
- 2013-03-28 SG SG11201405944PA patent/SG11201405944PA/en unknown
- 2013-03-28 NZ NZ630219A patent/NZ630219A/en not_active IP Right Cessation
- 2013-03-28 US US14/387,707 patent/US9554999B2/en active Active
- 2013-03-28 WO PCT/US2013/034364 patent/WO2013149013A1/en active Application Filing
- 2013-03-28 ES ES13716655.9T patent/ES2557805T3/es active Active
- 2013-03-28 IN IN8538DEN2014 patent/IN2014DN08538A/en unknown
- 2013-03-28 PE PE2014001494A patent/PE20142302A1/es not_active Application Discontinuation
- 2013-03-28 KR KR1020147029784A patent/KR102123129B1/ko active IP Right Grant
- 2013-03-28 PT PT137166559T patent/PT2723323E/pt unknown
- 2013-03-28 AU AU2013237985A patent/AU2013237985B2/en not_active Ceased
- 2013-03-28 MX MX2014011483A patent/MX359654B/es active IP Right Grant
- 2013-03-28 CA CA2867649A patent/CA2867649C/en active Active
- 2013-03-28 JP JP2015503612A patent/JP6178402B2/ja active Active
- 2013-03-28 RS RS20150867A patent/RS54513B1/en unknown
- 2013-03-28 PL PL13716655T patent/PL2723323T3/pl unknown
- 2013-03-28 BR BR112014024057A patent/BR112014024057A8/pt not_active Application Discontinuation
- 2013-03-28 WO PCT/US2013/034464 patent/WO2013149074A1/en active Application Filing
- 2013-03-28 EP EP13716655.9A patent/EP2723323B1/en active Active
- 2013-03-28 DK DK13716655.9T patent/DK2723323T3/da active
- 2013-03-28 CN CN201380022948.0A patent/CN104271118B/zh active Active
- 2013-03-28 SI SI201330112T patent/SI2723323T1/sl unknown
- 2013-11-27 US US14/091,608 patent/US8748396B2/en active Active
- 2013-11-27 US US14/091,712 patent/US8748397B2/en active Active
-
2014
- 2014-08-29 HK HK14108816.9A patent/HK1197174A1/zh unknown
- 2014-09-16 IL IL234688A patent/IL234688B/en active IP Right Grant
- 2014-09-25 ZA ZA2014/06982A patent/ZA201406982B/en unknown
- 2014-09-25 CR CR20140449A patent/CR20140449A/es unknown
- 2014-09-25 CL CL2014002553A patent/CL2014002553A1/es unknown
- 2014-09-29 CU CUP2014000116A patent/CU20140116A7/es unknown
- 2014-09-30 CO CO14216241A patent/CO7081146A2/es unknown
- 2014-10-22 MA MA37445A patent/MA37445B1/fr unknown
- 2014-10-24 EC ECIEPI201424363A patent/ECSP14024363A/es unknown
-
2015
- 2015-07-02 HK HK15106290.7A patent/HK1205685A1/xx unknown
- 2015-08-06 HK HK15107596.6A patent/HK1206979A1/xx unknown
- 2015-12-18 HR HRP20151392T patent/HRP20151392T1/hr unknown
- 2015-12-21 SM SM201500320T patent/SMT201500320B/it unknown
- 2015-12-22 CY CY20151101180T patent/CY1117380T1/el unknown
-
2017
- 2017-10-06 AU AU2017239624A patent/AU2017239624B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017239624B2 (en) | Lyophilization of synthetic liposomal pulmonary surfactant | |
CA2520979C (en) | Formulations of ecteinascidins | |
US7582312B2 (en) | Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof | |
JP2007526329A (ja) | 賦形剤の結晶化を改善するための凍結乾燥法 | |
Chen et al. | The freeze-thawed and freeze-dried stability of cytarabine-encapsulated multivesicular liposomes | |
JPH04234820A (ja) | 長期作用持続性リポソームペプチド薬学的生成物およびそれらの調製方法 | |
US10307431B2 (en) | Lyophilized cyclophosphamide composition and methods of preparation thereof | |
SU978715A3 (ru) | Способ получени водного раствора простациклина или его соли | |
JP6568846B2 (ja) | Hgf凍結乾燥製剤 | |
US20090298780A1 (en) | Methods To Produce Lung Surfactant Formulations Via Lyophilization And Formulations And Uses Thereof | |
US20180104264A1 (en) | Method for Preparing Lyophilized Organic Solvent-Free Cyclophosphamide | |
CN118215469A (zh) | 新的脂肽制剂 | |
JP5265514B2 (ja) | Hgf製剤 | |
JP2000072661A (ja) | 凍結乾燥法 |